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Available online xxxxBackground: Neutrophil depletion improves neurologic outcomes in experimental sepsis/brain injury. We hy-
pothesized that neutrophils may exacerbate neuronal injury through the release of neurotoxic quantities of
the neurotransmitter glutamate.
Methods: Real-time glutamate release by primary human neutrophils was determined using enzymatic biosen-
sors. Bacterial and direct protein-kinase C (Phorbol 12-myristate 13-acetate; PMA) activation of neutrophils in
human whole blood, isolated neutrophils or human cell lines were compared in the presence/absence of N-
Methyl-D-aspartic acid receptor (NMDAR) antagonists. Bacterial and direct activation of neutrophils from wild-
type and transgenic murine neutrophils deficient in NMDAR-scaffolding proteins were compared using flow cy-
tometry (phagocytosis, reactive oxygen species (ROS) generation) and real-time respirometry (oxygen con-
sumption).
Findings: Both glutamate and the NMDAR co-agonist D-serine are rapidly released by neutrophils in response to
bacterial and PMA-induced activation. Pharmacological NMDAR blockade reduced both the autocrine release of
glutamate, D-serine and the respiratory burst by activated primary human neutrophils. A highly specific small-
molecule inhibitor ZL006 that limits NMDAR-mediated neuronal injury also reduced ROS by activated neutro-
phils in amurinemodel of peritonitis, via uncoupling of the NMDARGluN2B subunit from its' scaffolding protein,
postsynaptic density protein-95 (PSD-95). Genetic ablation of PSD-95 reduced ROS production by activatedmu-
rine neutrophils. Pharmacological blockade of the NMDAR GluN2B subunit reduced primary human neutrophil
activation induced by Pseudomonas fluorescens, a glutamate-secreting Gram-negative bacillus closely related to
pathogens that cause hospital-acquired infections.
Interpretation: These data suggest that release of glutamate by activated neutrophils augments ROS production in
an autocrine manner via actions on NMDAR expressed by these cells.
Fund: GLA: AcademyMedical Sciences/Health Foundation Clinician Scientist. AVG is aWellcome Trust Senior Re-
search Fellow.
© 2019 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Neurologic dysfunction is strongly linked to adverse outcomes and
excess mortality in critical illness yet is often unrelated to the inciting
pathology [1]. Themechanisms underlying neurologicmorbidity in crit-
ical illness remain incompletely understood, but systemic inflammation
[2] and alterations in N-methyl-d-aspartate receptor (NMDAR) signal-
ling are common features [3,4].er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
t al., NMDA receptor modulation of glutamate release in activated
Research in context
Evidence before this study
Neurologic dysfunction is strongly linked to adverse outcomes in
critical illness, yet often unrelated to the inciting pathology. The
mechanisms underlying neurologic morbidity in critical illness re-
main incompletely understood, but systemic inflammation and al-
terations in N-methyl-D-aspartate receptor signalling are common
features.
Added value of this study
Our data suggest that autocrine release of potentially neurotoxic
quantities of glutamate in activated neutrophils augments ROS
production.
Implications of all the available evidence
NMDAR signalling modulates acute inflammation, contributing to
neurologic injury. These findings suggest that neutrophils may
contribute to neurologic infection and injury by mimicking gluta-
mate release synonymous with neuronal injury.
2 A.G. del Arroyo et al. / EBioMedicine xxx (2019) xxxA significant contributor to brain injury is the release of neurotoxic
quantities of the neurotransmitter glutamate, [5] which activates in-
tracellular protein kinase-C (PKC) and neuronal NADPH oxidase lead-
ing to the injurious production of superoxide [6,7]. NADPH oxidase
not only contributes to the generation of superoxide in neuroinflam-
mation and neurodegeneration [8] but also a range of immune cells
[9]. Activated human immune cells, including myeloid cells, release
glutamate [10] [11,12]. Since innate immunity is directly involved in
neuronal deterioration after injury [13] and infection [14,15], immune
cells may directly contribute to elevated levels of glutamate. Blood
glutamate concentrations of patients with brain injury and/or trauma
are higher than those in healthy volunteers [16]. Moreover, depletion
of neutrophils after neuronal injury secondary to subarachnoid haem-
orrhage reduces tissue inflammation and cognitive function in mice,
which is associated with changes in neuronal NMDAR subunit
composition [17].
Gene expression studies in human neutrophils implicate changes in
NMDAR following systemic inflammation triggered by trauma [18].
However, blood levels of glutamate are substantially higher (~60 μM)
than levels measured in the brain (0.2–20 μM) [19] and do not activate
neutrophils in the absence of danger-associated or pathogen-associated
molecular patterns. If glutamate contributes to neutrophil activation via
NMDAR, it is therefore likely that PKC activation increases the probabil-
ity of NMDA channel opening by reducing the voltage-dependentMg2+
block of NMDA-receptor channels, as demonstrated by studies in
neurons [20].
Here, we examined whether neutrophils may contribute to the
pathobiology of systemic inflammation through the regulated re-
lease of neurotransmitters signalling mechanisms harnessed by
NMDAR. Our findings suggest that neutrophils and neurons share
regulatory mechanisms that provide translational insight into how
a variety of clinical interventions play a hitherto unappreciated
role in interfering with NMDA modulation of innate immunity in
the clinical setting.
2. Materials and methods
All experimentswere performed in accordwith theUKAnimals (Sci-
entific Procedures) Act (1986) and ARRIVE guidelines [Supplemental
Methods].Please cite this article as: A.G. del Arroyo, A. Hadjihambi, J. Sanchez, e
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2.1.1. Primary human neutrophils
All subjects provided written consent for blood collection, following
ethical committee approval. (MREC:11/H0722/3). Neutrophils in whole
blood and/or isolated human neutrophils were obtained using Ficoll
separation followed by positive selection with CD16 microbeads
(Miltenyi Biotec, Bisley, UK) achieving N98.5% purity, as assessed by
CD16+ surface staining. SiRNA knockdown targeted against GluN1
and GluN2B in primary human neutrophils was undertaken using elec-
troporation (Amaxa nucleofector II, Lonza). Full siRNAs sequences are
provided in Supplementary data.
2.1.2. Human neutrophil-like cell line
HL60 cells obtained fromATCC (CCL-240™) were differentiated into
neutrophils by adding 1.25% DMSO for 6 days. GluN1B was knocked
down in HL60 cells prior to differentiation, using five short hairpin
RNA lentiviral clones expressing the pLKO.1-puromycin vector (MIS-
SION shRNA, Sigma, Poole UK; see Supplementary data for full details).
We compared the phenotype of the clone that resulted in the highest
knockdownofGluN1Bwith cloneswhere lentiviral transfectionwas un-
successful/minimal. Gene expression was quantified by quantitative
PCR performed with SYBR Green Supermix (Roche) on an Eppendorf
Realplex system. Gene expressionwas analyzed using theΔΔCtmethod,
related to expression in the LN229 neuroblastoma cell line [21] (see
Supplementary data for primer details).
2.1.3. Murine neutrophils
C57BL/6 mice were obtained from Charles River UK. PSD-95−/−
mice were obtained from the Wellcome Trust Sanger Institute. Female
and male mice aged 7–12 weeks were used, with each serving as their
own control. Neutrophils were isolated from either bone marrow or
peritoneal exudates. Bone marrow derived neutrophils, which have
similar respiratory burst and phagocytic characteristics to blood neutro-
phils [22], were extracted from age and gender-matchedmice after cer-
vical dislocation to avoid the potential confounding effects of
inhalational anaesthesia on NMDAR activity [10]. Non-viable cells
were excluded by7AAD staining. Neutrophilswere identified by Ly6G+-
Ly6C−CD11bhi staining. For peritoneal neutrophil harvest, zymosan
(1 mg·g−1; Sigma, UK) was injected intraperitoneally in C57B/6 wild-
type mice of either gender (age 6–8 weeks) prior to lavage with 5 ml
ice cold PBS 3 h later. Highly purified neutrophils were obtained by neg-
ative selection using a neutrophil isolation kit (MACS Miltenyi Biotec),
achieving ≥98% purity.
2.2. Measurement of glutamate and D-serine release
The design and operation of enzyme-based glutamate by microelec-
trode biosensors have been described previously [23]. The glutamate
biosensor contains glutamate oxidase, which converts glutamate to α-
ketoglutarate, driving production of NH3 and H2O2. The glutamate bio-
sensor amperometrically detects H2O2 produced within the thin enzy-
matic layer around the microelectrode tip with a response time of
b10 s. D-Serine biosensor currents are generated by D-Amino acid oxi-
dase (DAAO) catalyzing the oxidative deamination of D-serine. We con-
trolled for the release of non-specific electroactive species by placing a
null sensor, which lacks enzymes, into a non-adherent heated well
(37 °C) containing 1.5 × 106 neutrophilsml−1 in PBS. Changes in electri-
cal potential of the biosensors weremeasured using a potentiostat. Sen-
sors were calibrated before and after every experiment to measure the
sensitivity of the biosensors. Changes in extracellular calcium concen-
tration in whole blood were measured using an ionised calcium elec-
trode (ABL625, Radiometer, Copenhagen, Denmark). NMDA (20 μM)
and D-serine (5 μM) were also added to human whole blood or isolated
neutrophils to assess the impact of acute extracellular increases of theset al., NMDA receptor modulation of glutamate release in activated
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itor diphenyleneiodonium chloride (10 μM).
2.3. Confocal and fluorescent calcium imaging
Human primary neutrophils were plated on Cell-Tak coated cover-
slips prior to incubation with polyclonal antibodies and/or blocking
peptide (see Supplemental Digital content). Cultures were imaged
(Zeiss LSM 510 or Zeiss 800 laser scanning microscope, with either a
20× (N.A.-0.8) or a 40× (NA 1.3) objective). For fluorescent Ca2+ imag-
ing studies, HL60 cells differentiated into the neutrophil-like state were
loaded for 30 min at room temperature with 5 μM Fura-2 AM and
0.005% pluronic in HEPES-buffered salt solution (HBSS) containing
156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 mM
CaCl2, 10 mM glucose, and 10 mM HEPES (pH 7.35). PMA was added
first, followed by NMDA [24]. All the experiments were conducted at
37 °C. Fluorescent imaging was performed using an inverted micro-
scope (I × 71; Olympus, Japan), a high-numerical-aperture oil-
immersion objective (60×, 1.65 NA) and a cool-charge-coupled-device
camera (Andor, USA). Images were acquired and analyzed using
Andor IQ software (Andor, USA). [Ca2+]i was monitored in single cells
using excitation light provided by a xenon arc lamp, the beam passing
through a monochromator sequentially at 340 and 380 nm (Cairn Re-
search, Kent, UK). The Fura-2 fluorescence was not calibrated in terms
of [Ca2+]i because of the difficulty in deconvoluting the strength of the
signal from the amount of dye taken up by each cell. The Fura-2 ratio
is defined as the ratio of fluorescence emission upon excitation at
340 nm (Ca2+-bound form) to emission upon excitation at 380 nm (un-
bound fluorophore).
2.4. Flow cytometry
Neutrophils were identified using forward and side scatter charac-
teristics (Supplementary Figs. 1–3), in combination with specific cell
surface antigen for CD16 (clone VEP13), CD14 (clone TUK4) and
CD11b (clone M1/70.15.11.5) or the appropriate isotype control (all
Miltenyi Biotec). Intracellular staining was performed using BD
Cytofix/Cytoperm™ Fixation/Permeabilization Kit (BD Biosciences, Ox-
ford, UK). Serine racemase (clone 7E8) antibody was acquired from
Abcam (Cambridge, UK). NMDAR subunits and associated scaffolding
proteins were quantified with appropriate secondary antibodies or
isotypes as controls, using validated antibodies as indicated: NMDAε1
antibody (clone H-54 rabbit polyclonal IgG); sc-9056, Santa Cruz [25];
NMDAζ1 Antibody (clone C-20; goat polyclonal IgG), sc-1467 (conju-
gated with phycoerythrin), Santa Cruz [26]; GluN2B-FITC (IgG linear
peptide corresponding to mouse NR2B; FCABS332F, Merck Millipore);
PSD-95 antibody (clone H-40, rabbit polyclonal IgG, sc-28,941; Santa
Cruz) [27]; SAP102 (NE-dlg, 7H11; sc-134,400, Santa Cruz). Flow cy-
tometry dot plots were based on comparison with isotype controls,
fluorescence minus one (FMO), permeabilized and unpermeabilized
unstained cells. Acquired data (Cyan ADP (Beckman Coulter, MI USA);
FACSCalibur) were analyzed using Kaluza (Beckman Coulter, MI USA)
and/or CellQuest (BD Biosciences, Oxford, UK) software.
2.5. Neutrophil function
Three separate experimental models were employed: (i) highly pu-
rified human neutrophils, (ii) humanwhole blood and (iii) murine neu-
trophils recruited in response to zymosan peritonitis.
2.5.1. Neutrophil oxidative burst
Opsonized Escherichia coli (3 × 106 bacteria), fMLP (5 μM), PMA (0.9
μM)orwash solution (negative control)were added to blood or isolated
neutrophils for 10min at 37 °C in awater bath. Respiratory burst activity
was assessed using dihydrorhodamine-123 (Phagoburst®, Orpegen,
Germany). After paraformaldehyde fixation, quantification of ROS wasPlease cite this article as: A.G. del Arroyo, A. Hadjihambi, J. Sanchez, e
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phil population.
2.5.2. Neutrophil oxygen consumption
We used real-time respirometry (Seahorse XF, North Billerica, MA,
USA) to quantify oxygen consumption in human, murine and HL60
cells (0.2–1 × 106 cells/well). Co 101244 (25–250 μM) or medium
were injected, 10 min prior to injection of vehicle control (DMSO) or
PMA (500ɳM; Sigma-Aldrich).
2.5.3. Neutrophil phagocytosis
200 μl heparinized whole peripheral blood was incubated with 40 μl
opsonized FITC-labeled Escherichia coli for 10 min at 37 °C in a water
bath. Samples remaining on ice served as negative controls. To stop
phagocytosis, 200 μl Phagotest® quenching solution was added to
each sample at the end of the incubation time. Samples were then
washed with 3 ml Phagotest® washing solution twice and lysed with
2 ml Phagotest® lysis solution for 20 min at room temperature. PI ex-
cluded dead/non-viable cells. After a further wash, neutrophils were ei-
ther processed immediately or stained with anti-CD16–APC for 20 min
at 4 °C, before the final assay step. Neutrophil subsets were defined ac-
cording to their scatter properties and CD16+ expression. Experiments
with a minimum n = 4, performed in 3 separate experiments.
2.6. Bacterial culture
The glutamate-producing bacillus Pseudomonas fluorescens prolifer-
ates in mouse brain homogenates at 4 °C.(Tatara et al., 2008) We incu-
bated P. fluorescens (106 cfus·ml−1) with 3 × 106 highly purified (97 ±
1%) primary human neutrophils (106·ml−1) obtained from healthy vol-
unteers (n= 4) for 18 h in Dulbecco's Modified Eagle's medium (with-
out antibiotics). Co 101244 (10–1000 μM) or vehicle control were
added to these samples. This strain was resistant to penicillin, cephalo-
sporins and clindamycin (Royal Veterinary College Diagnostic Laborato-
ries, North Mymms, Herts UK).
2.7. Immunoblots
Membranes were incubated with the following primary antibodies
(from Santa Cruz Biotechnology, Heidelberg, Germany, unless other-
wise stated): GluN1 (sc-9056), NE-dlg (SAP102; sc-134,400), PSD-95
(sc-28,941), ERK (1:1000; Cell Signaling Technology, Leiden; #4695),
phospho-ERK (1:1000; Cell Signaling Technology, Leiden; #4370), AKT
(1:1000; Cell Signaling Technology, Leiden; #9272), phospho-AKT
(S473) (1:1000; Cell Signaling Technology, Leiden; #9271), NOX-2
(1:1000; Abcam, Oxford; ab129068). Loading control used was
GAPDH (1:1000; Cell signaling). Secondary antibodies (1:2000; Dako,
Stockport, UK or Cell Signaling Technology, Leiden) were rabbit anti
mouse HRP or goat anti-rabbit HRP, as indicated. Membranes were de-
veloped using ECLTM reagent and Hyperfilm ECL (Amersham, UK).
2.8. Replicates
Each experiment was performed at least 3 times, with ≥3 indepen-
dent biological data points obtained.
2.9. Statistics
2.9.1. Randomisation and blinding
All samples/mice were randomised to receive specified interven-
tions, using Research Randomizer [28]. Analyzers were blinded to the
identify of treatments/genotypes.
2.9.2. Statistical testing
Data were processed by analysers blinded to group assignments. For
experiments with values measured over time, 2-way ANOVA analysist al., NMDA receptor modulation of glutamate release in activated
4 A.G. del Arroyo et al. / EBioMedicine xxx (2019) xxxwas used. Student's t-tests was used for normally distributed data, hav-
ing applied the Kolmogorov-Smirnov normality test. P values b 0.05
were considered significant.
2.9.3. Sample size estimation
For paired samples, to detect a mean difference of 30% (±20 SD) in
dihydrorhodamine fluorescence, ≥7 samples per group would be re-
quired (α= 0.05; 1-β= 0.9; two-tailed). For unpaired samples, to de-
tect a mean difference of 20 percentage points (±10 SD) in
dihydrorhodamine fluorescence, ≥6 samples per group would be re-
quired (α= 0.05; 1-β= 0.9; two-tailed). Sample size and statistical
analyses were performed using NCSS 11 software (Kaysville, Utah,
USA).
3. Results
3.1. Release of glutamate by activated neutrophils
In whole blood, a rapid decline in ionised calcium after PMAwas ob-
served, indicating that high calcium permeabilitymay contribute to pri-
mary neutrophil activation (Fig. 1A). Glutamate excess damages
neurons through facilitating calcium influx and neuronal release of su-
peroxide by activating neuronal NADPH oxidase [7]. This process is pre-
dominantly mediated by GluN2B NMDAR subunit-scaffolding protein
interactions [29]. We confirmed GluN2B subunit transcription and pro-
tein expression in both primary neutrophils and HL60 neutrophil-like
cells (Supplementary data). Stimulation of either isolated human neu-
trophils or heparinized whole blood with either opsonised EscherichiaFig. 1. Release of glutamate and D-serine by activated human neutrophils. A) Ionised calcium fa
blood samples before and after PMA (*p b 0.01, paired t-test, n= 5 separate samples). B) Real-t
trophils before and after application of Escherichia coli inwhole blood. Glutamate biosensor was
enzymes, detects release of non-specific electroactive species. The difference between glutama
lease by isolated primary human neutrophils before and after application of PMA. PMA-induce
sensors were calibrated with 30 μM glutamate at the end of the experiment. The null sensor
primary human neutrophils following PMA-activation in the presence/absence of Co 101244
that serine racemase is present on cell surface of CD16+primaryhumanneutrophils. Superimpo
release by isolated primary human neutrophils before and after application of PMA. D-serine bio
for D-serine release from isolated primary human neutrophils following PMA-activation in the p
Please cite this article as: A.G. del Arroyo, A. Hadjihambi, J. Sanchez, e
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or PMA (Fig. 1C) induced rapid release of glutamate in micromolar
quantities (Fig. 1D). Given the rapid, substantial rise in glutamate after
neutrophil activation and accompanying decline in calcium in whole
blood, we next tested whether GluN2B blockade may reduce glutamate
release.We found that glutamate releasewas reduced in thepresence of
the specific GluN2B antagonist Co 101244 (Fig. 1C,D).
In neurons, D-serine is a key determinant of glutamate neurotoxicity,
acting at the NMDAR as a co-agonist [31]. Serine racemase, the enzyme
which converts L-serine to D-serine, [32] was present on the surface of
human neutrophils (Fig. 1E). Accordingly, we also detected significant
release of D-serine following opsonised Escherichia coli (Supplementary
data) or PMA stimulation of primary human neutrophils (Fig. 1F). Aswe
foundwith glutamate, D-serine releasewas also reduced in the presence
of the specific GluN2B antagonist Co 101244 (Fig. 1G).
Direct application of NMDA and D-serine (at similar concentrations
to those we found released following neutrophil activation) caused
rapid loss of surface CD16+ in isolated primary human neutrophils
(Supplementary Fig. 4), indicative of apoptosis [33]. By contrast, there
wasminimal change in surface CD11b expression, which increases dra-
matically when neutrophils are activated [34] or reactive oxygen spe-
cies either in the presence or absence of the ROS inhibitor
diphenyleneiodonium chloride (Supplementary Fig. 4).
3.2. GluN2B NMDAR subunit augments neutrophil ROS production
In neurons, high levels of glutamate cause tissue injury by calcium
influx through the GluN2B NMDAR subunit, which results in neuronallls in whole human blood after PMA stimulation; calcium levels are shown from the same
ime recordings of glutamate release (negative deflection) by isolated primary human neu-
calibratedwith 40 μMglutamate at the end of the experiment. The null sensor, which lacks
te and null sensor readings quantifies glutamate. C) Real-time recordings of glutamate re-
d glutamate release was reduced in the presence of Co 101244 (100 μM). Glutamate bio-
detects non-specific interferents. D) Summary data for glutamate release from isolated
(100 μM; n = 10 separate samples; * p b 0.05, by paired t-test). E) Density plot showing
sed lines showFMO/isotype control defined boundaries. F) Real-time recording of D-serine
sensorswere calibratedwith 1 μMD-serine at the end of the experiment. G) Summary data
resence/absence of Co 101244 (100 μM; n=10 separate samples; * p b 0.05, paired t-test).
t al., NMDA receptor modulation of glutamate release in activated
5A.G. del Arroyo et al. / EBioMedicine xxx (2019) xxxNADPH oxidase generating ROS [7]. Since neutrophil depletion exacer-
bates neuronal injury in subarachnoid haemorrhage, we next explored
whether selective blockade of the NMDAR GluN2B similarly reduces
ROS generation in neutrophils using two separate experimentalmodels.
First, in isolated human neutrophils (purity N 98%), pharmacological
blockade of the GluN2B subunit using Co 101244 reduced ROSFig. 2.GluN2BNMDAR subunitmodulates neutrophil ROS production. (A) Histograms illustratin
by 123-dihydrorhodamine) triggered by lipopolysaccharide (100 ng·ml−1), fMLP, and opsonise
(B) Population data for GLuN2B antagonist Co 101244 on ROS generation (quantified by 123-dih
as %PMA response (i.e. PMA alone with no GluN2B antagonist present; *p b 0.05, ANOVA; n =
123-dihydrorhodamine) from CD16+ neutrophils in whole blood samples following E Coli a
present; mean ± sem, n = 3–7/group; *p b 0.01, ANOVA). (D) Oxygen consumption (measu
isolated highly purified (N98%) primary human neutrophils pretreated with Co 101244 (25–
ANOVA, (drug × time)). (E) Primary human neutrophil phagocytosis of opsonized FITC-labe
samples, paired t-test). (F) ROS generation in microbead purified peritoneal neutrophils (Ly6G
antagonist Co 101244 was incubated with isolated cells for 30 minutes ex-vivo in presence/ab
by 123-dihydrorhodamine) expressed as %PMA response (i.e. PMA alonewith noGluN2B antago
ROS in lavage neutrophils and after stimulation with PMA (p b 0.01, paired t-Test; n = 10 mic
Please cite this article as: A.G. del Arroyo, A. Hadjihambi, J. Sanchez, e
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terial peptide N-formyl Methionyl-Leucyl-Phenylalanine (fMLP),
opsonised E. coli and the direct protein kinase C agonist PMA (Fig. 2A,
B). Consistent with flow cytometry-based measurements of ROS gener-
ation (Fig. 2C), pharmacologic blockade of GluN2B also reduced cellular
oxygen consumption (the most accurate physiologic measure ofg effect of GluN2B receptor antagonist Co 101244 (100 μM) onROS generation (quantified
d E coli (3 × 106·ml−1) inwhole blood preparation and direct PKC stimulation using PMA.
ydrorhodamine) in primary human neutrophils after ligands shown in panel A, presented
5–8). (C) Co 101244 in submicromolar concentrations reduces ROS release (quantified by
nd PMA, standardized as % of PMA response (i.e. PMA alone with no GluN2B antagonist
red by direct respirometry (Seahorse XF96)) before, and following, PMA-stimulation in
250 μM) or phosphate-buffered saline control (mean ± sem, *p b 0.05; n = 5, one-way
led E coli is reduced by GluN2B antagonist Co 101244 (100 μM; *p b 0.05; n = 5 patient
+) obtained 3 h after intraperitoneal injection of 1 g/g zymosan in C57B/6 mice. GluN2B
sence of PMA. (G) Graph shows summary data for peritoneal neutrophil ROS (quantified
nist present) after IP zymosan alone and PMA post-peritoneal harvest. Co 101244 reduced
e; mean ± sem).
t al., NMDA receptor modulation of glutamate release in activated
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trophils (Fig. 2D). In keeping with the observation that genetic NADPH
oxidase deficiency results in a decreased ability of neutrophils to phago-
cytose opsonised bacteria [35], selective GluN2B blockade reduced bac-
terial phagocytosis in primary human neutrophils (Fig. 2E).
Second, in amurinemodel, we explored howNMDARmaymodulate
zymosan-induced peritoneal inflammation,which is characterized at anFig. 3. Maturation of GluN2B NMDAR subunit expression in primary human granulocytes a
neutrophils, undifferentiated (designated as HL60-) and HL60 cells differentiated with DMSO
(which expresses NMDAR in low quantities). GluN2B mRNA was higher in DMSO-differen
neutrophil-like HL60 cells following 3 days (blue line) or 6 (red line) days treatment with 1
Numbers above histograms indicate days of DMSO treatment. (C) Confocal images (Zeiss
blocking peptide anti- GluN2B Receptor (extracellular), conjugated to ATTO-594 (1:500; Alom
(D) Differentiation of HL60 cells with 1.25% DMSO into neutrophil-like cells for up to 6 days is
PMA stimulation, compared to HL60 cells differentiated for 3 days with 1.25% DMSO. n = 3–5
like cell line. (F) Effect of shRNA knockdown of GluN1 in HL60-neutrophil like cell line PMA-ind
dent experiments). (G) Oxygen consumption (measured by direct respirometry (Seahorse XF9
HL60 cells (mean± sem, *p b 0.01; n=5, ANOVA).White and black circles represent unstimula
microscopy expression of GluN2B 24 h after transfection of primary human neutrophils with ei
units. (I) Representative histograms of ROS production (quantified by 123-dihydrorhodamine)
indicate Alexa-647 transfected cells (mean (SD)) 22 ± 3% neutrophils were transfected, as det
data for siRNA knockdown experiments in human primary cells, before (baseline) and after P
versus GluN1 or GluN2B siRNA after PMA stimulation; ANOVA).
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inhibition of the NMDAR GluN2B reduced ROS generation by Ly6G+
peritoneal neutrophils elicited by intraperitoneal zymosan. Pharmaco-
logic inhibition of the NMDAR GluN2B subunit further suppressed ROS
generation elicited by PMA applied ex-vivo after intraperitoneal
zymosan (Fig. 2G).nd neutrophil-like HL60 cells. (A) RT-PCR showing GluN2B mRNA in primary human
for 6 days (designated as HL60+), referenced to human neuroblastoma LN229 cell line
tiated cells (p b 0.01; n = 5; mean ± sem) (B) GluN2B expression in differentiated
.25% DMSO (dimethyl sulfoxide). Isotype control is shown in grey for both timepoints.
LSM 510) showing cell surface staining for GluN2B, in absence or presence of specific
one antibodies, Israel). Lower panel shows extracellular co-staining of GluN2B and CD16.
associated with higher increase in ROS (quantified by 123-dihydrorhodamine) following
group; 3 independent experiments. (E) shRNA knockdown of GluN1 in HL60-neutrophil
uced ROS production, as quantified by 123-dihydrorhodamine (*p b 0.05; n= 3 indepen-
6)) following PMA-stimulation in scrambled (red circles) or GluN1 deficient (blue circles)
ted control cells for each scrambled or GluN1 deficient genotype, respectively. (H) Confocal
ther scrambled siRNA, or siRNA targeted at knocking down GluN1 or GluN2B NMDAR sub-
following PMA activation of primary human neutrophils 24 h after transfection. Black areas
ermined by flow cytometric analysis of Alexa-647 conjugated to siRNA. (J) Summary ROS
MA stimulation (mean ± sem, *p b 0.05; n = 3, comparing ROS generation in scrambled
t al., NMDA receptor modulation of glutamate release in activated
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neutrophils
Since mature neutrophils release more ROS, we examined whether
GluN2B expression changed when HL60 cells are differentiated into
neutrophil-like cells. Undifferentiated HL60 cells showed low levels of
GluN2B subunit expression, similar to the low quantities known to be
expressed in the human neuroblastoma LN229 cell line ([21]; Fig. 3A).
An increase in GluN2B subunit transcription (Fig. 3A) and protein ex-
pression (Fig. 3B) was observed following differentiation into a
neutrophil-like phenotype (Collins et al., 1979). GluN2B was also
expressed in highly purified primary CD16+ neutrophils (Fig. 3C).
GluN2B subunit upregulation was associated with higher ROS produc-
tion in response to PMA (Fig. 3D).Wenext assessedwhether genetic re-
duction in GluN2B expression altered ROS production, by using a short
hairpin RNA to reduce the obligatory GluN1 subunit that is required
for GluN2B expression [36], by ~50% (Fig. 3E). It should be noted that
the HL60 cell line has higher constitutive ROS production, in contrast
to primary neutrophils (as demonstrated by baseline ROS quantifica-
tion; Fig. 3F). Nevertheless, GluN2B subunit upregulation was associ-
ated with higher ROS production in response to PMA (Fig. 3F). In
differentiated HL60-neutrophil like cells. GluN1 deficient wasFig. 4.Modulation of NMDAR gating. (A) Apoptosis in isolated primary human neutrophils is a
within normal limits. (mean (SE); n = 6 individuals' samples). Representative density plots o
neutrophil ROS in human whole blood was augmented following extracellular magnesi
supplementing the blood with calcium chloride. For clarity, unstained unstimulated control o
(quantified by 123-dihydrorhodamine) in human whole blood remained unaffected by delaye
= 10 individuals/group, p b 0.01, ANOVA). Plasma calcium was maintained within normal lim
(500 μM). Colour traces depict changes in intracellular [Ca2+] in five individual HL60 cells ove
to trigger Ca2+ responses in HL60 mutant cell line where the GluN1 gene was knocked down b
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stimulation (Fig. 3G). siRNA targeted at knocking down GluN1 or
GluN2B in primary human neutrophils (Fig. 3H, I) also reduced ROS
after PMA stimulation (Fig. 3J).
3.4. PKC activation facilitates NMDARmodulation of neutrophil function by
calcium influx
We next further examined why circulating neutrophils do not ap-
pear tomount a respiratory burst in the presence of high concentrations
of blood glutamate alone. Phosphorylation of protein kinase C was not
affected by pharmacologic GluN2B inhibition in primary human neutro-
phils, as assessed by immunoblot and flow cytometry (Supplementary
Fig. 5).We examinedwhether thismay be explained by a critical feature
of NMDAR neuronal biology, which requires PKC activation to increase
the probability of NMDA channel opening by reducing voltage-
dependentMg2+ block of NMDA-receptor channels [20]. In isolated pri-
mary neutrophils, Mg2+ reduced neutrophil apoptosis in the presence
of extracellular calcium (Fig. 4A). In whole blood, extracellular magne-
sium was depleted using EDTA. PMA-induced ROS in primary human
neutrophils was augmented in the following depletion of magnesium,
with plasma calcium maintained within normal limits by adding backugmented when extracellular magnesium is absent. Extracellular calcium was maintained
f annexin V and PI expression shown from 3 independent experiments. (B) PMA-induced
um depletion using EDTA. Plasma calcium was maintained within normal limits by
mitted. ROS was quantified by 123-dihydrorhodamine. (C) PMA-induced neutrophil ROS
d add-back of magnesium to restore normal plasma levels (≥0.8 mmol L−1; mean (SE); n
its. (D) Calcium oscillations in HL60 neutrophil-like cells triggered by PMA and NMDA
r time, representative of 3 separate experiments. (E) Neither PMA nor NMDA were able
y shRNA.
t al., NMDA receptor modulation of glutamate release in activated
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whole blood remained unaffected by delayed add-back of magnesium
to restore normal plasma levels (≥0.8 mmol L−1). Using HL60
neutrophil-like cells, we found that NMDA application only after PMA
treatment induced Ca2+ oscillations (Fig. 4D). Neither PMA nor NMDA
were able to trigger Ca2+ responses in a HL60 mutant cell line where
the GluN1 gene was knocked down by shRNA (Fig. 4D).
3.5. NMDAR scaffolding protein interactionwith nNOSmediates ROS gener-
ation by human neutrophils
NMDA receptor subunits (GluN1, GluN2A-D) form tetramers that
assemble via the cytoplasmic domain of GluN2B with MembraneFig. 5. GluN2B-MDAR scaffolding proteins modulate neutrophil ROS generation. (A) Histograms
with E. coli and PMA-which is reduced by ZL006 (1–50 μM) in purified primary human neutrop
dependent manner (10–50 μM; n = 7). (C) Summary data showing effect of ZL006 on PMA
expressed as % respective control (mean ± sem; n = 7 subjects; *p = 0.01, ANOVA). (D)
differentiated HL60 neutrophil-like cells. (E) PMA-induced ROS production (quantified by 12
and homozygous PSD-95 deficient. (F) Population data for ROS in wild-type and homozygous
*p = 0.02 unpaired t-test). (G) ERK phosphorylation in primary human neutrophils is reduce
in CD16+ cells, humanwhole blood (mean± sem; n=5 experiments; *p b 0.05; two-way (dr
ilar results obtained infive separate experiments. Numbers below123-dihydrorhodamine immu
antagonist Co 101244) or phosphate-buffered saline control. (H) PMA-induced ROS product
SAP102 deficient mice. (I) Population data for wild-type and homozygous SAP-102 deficient bo
t-test).
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Dlg4, SAP102/Dlg3, PSD93/Dlg2) to form super-complexes linked to
other receptors and signalling proteins [37]. In the absence of the scaf-
folding protein PSD-95, neuronal injury is reduced [38]. PSD-95 binds
both NMDARs and nNOS at excitatory synapses by assembling them
into macromolecular signalling complexes. Activation of nNOS requires
PSD-95 followingNMDAR-mediated excitotoxic calcium influx [39]. The
small-molecular inhibitor ZL006 selectively and potently blocks the in-
teraction of nNOS and PSD-95, through which focal cerebral ischemic
damage is reduced in animal models of stroke [29].We therefore tested
whether ZL006 also reduced neutrophil ROS generation; we found a
similar effect to that described in neurons in both primary human neu-
trophils (Fig. 5A) and whole blood samples challenged with opsonisedillustrating ROS generation (quantified by 123-dihydrorhodamine) following stimulation
hils (n= 7). (B) E. coli-induced ROS inwhole blood samples is reduced by ZL006 in a dose-
-induced ROS generation in neutrophils, as quantified by 123-dihydrorhodamine. Data
shRNA knockdown of GluN1B is associated with reduced nNOS protein expression in
3-dihydrorhodamine) is attenuated in bone-marrow derived neutrophils from wild-type
PSD-95 deficient bone marrow derived neutrophils (mean ± sem; n = 6–7 mice/group;
d by GluN2B antagonist Co 101244 following PMA-stimulation phospho-flow cytometry
ug × time) ANOVAwith Tukey posthoc comparison). Immunoblot above graph shows sim-
noblot denoteminutes after PMA stimulation (in the presence/absence of GluN2B subunit
ion is attenuated in bone-marrow derived neutrophils from wild-type and homozygous
ne marrow derived neutrophils (mean ± sem; n = 6–7 mice/group; *p= 0.04 unpaired
t al., NMDA receptor modulation of glutamate release in activated
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NMDAR scaffolding protein PSD-95-nNOS complex in neutrophils and
neurons (Fig. 5C). Consistent with these data, knockdown of GluN1 in
neutrophil-like HL60 cells was associatedwith a reduction in nNOS pro-
tein expression (Fig. 5D).
To further explore a potential role for PSD-95, we also tested to see if
PSD-95 genetic deficiency altered the neutrophil respiratory burst. Bone
marrow-derived neutrophils from PSD-95−/−mice (Fig. 5E) generated
less ROS following PMA challenge, as compared to neutrophils isolated
fromwild typemice (Fig. 5F). In the central nervous system,NMDAR ac-
tivation also triggers phosphorylation of ERK- a process involving
SAP102 scaffolding protein [40]. We found that blockade of GluN2B in-
hibits ERK phosphorylation in primary human neutrophils (Fig. 5G).
Furthermore, bone marrow-derived neutrophils obtained from
SAP102 deficient mice displayed reduced (40)ROS production in re-
sponse to PMA challenge (Fig. 5H), as compared to neutrophils isolated
from wild type mice (p b 0.05; n = 6/group; Fig. 5I).
3.6. Regulation of neutrophil apoptosis by NMDAR-mediated signalling
We next explored whether NMDAR-mediated mechanisms may
contribute to the viability of neutrophils, since neuronal viability isFig. 6. NMDAR modulation of neutrophil survival. (A) Annexin V versus propidium density pl
(scrambled shRNA) with shRNA knockdown of GluN1 (representative plots of n = 3 experim
cells where GluN1 expression was reduced. In contrast, MK801 increased baseline ROS in scr
differentiated, scrambled or GluN1deficient HL60-neutrophil like cell line. GAPDH served as lo
t-test. (C) Immunoblot for AKT and phosphorylation of AKT (1:1000;Cell Signalling) in different
control (Densitometry ratios summarised in graph; n= 3; * p= 0.04, by Students t-Test). (D) I
scrambled or GluN1deficient HL60-neutrophil like cell line. Total GAPDH (cytoplasmic and nuc
graph; n = 3).
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of pro-survival kinases [41,42]. In contrast to NMDAR-mediated neuro-
nal injury triggered by sustained elevations in extracellular glutamate,
activation of neuroprotective signalling cascades requires tonic, tran-
sient exposure of NMDAR to lower extracellular glutamate concentra-
tions [41,42]. Synaptic NMDAR-mediated signalling by glutamate is
coupled to the transcriptional control of the glutathione system [43],
thereby preventing apoptosis and maintaining neuronal activity [44].
Cell viability was assessed in differentiated neutrophil-like HL60 cells
where shRNA transfections reduced NMDAR expression. Application
of MK801, a non-competitive NMDAR blocker [45], did not reduce apo-
ptosis in cells when GluN1 expression was reduced (Fig. 6A). In HL60
cells where NMDAR expression was knocked down, the baseline rate
of apoptosis was enhanced and MK801 had no further effect (lower
panel, Fig. 6A). By contrast, NMDAR channel blockade by
MK801increased apoptosis of scrambled HL60 cells. In the same HL60
cell line, shRNA knockdown of NMDAR was associated with lower ex-
pression of NADPH oxidase (isoform 2; NOX2; Fig. 6B) and the pro-
survival kinase AKT (Fig. 6C), but not constitutively phosphorylated
ERK (Fig. 6D). These data suggest that NMDAR-mediated signalling
may contribute to neutrophil survival in a manner similar to that de-
scribed in neurons.ots to quantify constitutive apoptosis in HL60-neutrophil like cell line, comparing control
ents). Application of MK801, a non-competitive NMDAR blocker, failed to reduce ROS in
ambled cells. (B) Immunoblot for NADPH oxidase (isoform-2; 1:1000; Cell Signalling) in
ading control. Densitometry ratios summarised in graph; n = 3; * p = 0.02, by Students
iated, scrambled or GluN1deficient HL60-neutrophil like cell line. GAPDH served as loading
mmunoblot for ERK and phosphorylation of ERK (1:1000; Cell Signalling) in differentiated,
lear) served as loading control, hence dual band. (Densitometry ratios are summarised in
t al., NMDA receptor modulation of glutamate release in activated
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In pro-inflammatory states, NMDAR expression is upregulated in
non-neuronal, non-immune tissue such as cerebrovascular endothe-
lium [46]. Moreover, in trauma patients, NMDAR gene expression is
upregulated in neutrophils [18]. Therefore, we first examined
whether GluN2B NMDAR protein expression changed in neutrophils
following major surgery, where each sample was obtained from the
same individual before and 48 h after major surgery (Fig. 7A). A sig-
nificant increase in CD16+ neutrophil GluN2B expression was ob-
served postoperatively, a period characterized by elevatedFig. 7. GluN2B subunit in systemic inflammation and neurologic-related bacterial infection.
obtained from surgical patients preoperatively and 48 h after surgery, quantified using flow c
(mean± sem; p b 0.01, t-test; n= 6 patients assessed serially, preoperative versus postoperati
gical patient preoperatively and 2 days after surgery, quantified by 123-dihydrorhodamine. PBS
E. coli stimulation. (D) Neutrophil ROS generation following addition of PMA to whole blood, f
dihydrorhodamine. PBS control, Co101244 at 10 μM and 100 μMwas added to whole blood s
for preoperative and postoperative neutrophil responses to E coli in whole blood from 4 surg
for 10 min prior to stimulation. * denotes p = 0.001 for drug versus saline control comparison
measures ANOVA (time × drug treatment). (F) Summary data (median, interquartile range) fo
gical patients following pre-incubationwith PBS control, Co 101244 at 10 μMand 100 μMfor 10
0.07, comparison between pre versus postoperative values; by repeated measures ANOVA (tim
teers were incubated with GluN2B antagonist Co 101244 (0–100 μM shown) and Pseudomona
(quantified by 123-dihydrorhodamine fluorescence) in primary human neutrophils followin
12) = 5.8). (H) Example data from one volunteer showing increasing doses of Co 101244 redu
monas fluorescens.
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by reduced ROS generation in neutrophils stimulated by opsonised
E. coli (Fig. 7C) and PMA (Fig. 7D) postoperatively (summarised in
Fig. 5E–F).
3.8. GluN2B-mediated modulation of neurologic bacterial infection
P. aeruginosa accounts for up to ~18% of nosocomialmeningitis cases
after neurosurgery (O'Neill et al., 2006). We therefore further tested the
clinical relevance of our findings by examiningwhether a closely related
glutamate-producing bacillus, Pseudomonas fluorescens, modulated(A) Serial changes in GluN2B subunit expression in CD16+ primary human neutrophils
ytometry. (B) Population data for CD16+ GluN2B expression in the perioperative period.
ve). (C) Neutrophil ROS generation after E coli is added to whole blood from the same sur-
control, Co101244 at 10 μM and 100 μMwas added to whole blood sample 10min before
rom the same surgical patient preoperatively and 2 days after surgery, quantified by 123-
ample 10 min before E. coli stimulation. (E) Summary data (median, interquartile range)
ical patients following pre-incubation with PBS control, Co 101244 at 10 μM and 100 μM
; p = 0.035, ** denotes comparison between pre versus postoperative values; by repeated
r preoperative and postoperative neutrophil responses to PMA in whole blood from 4 sur-
min prior to stimulation. * denotes p=0.02 for drug versus saline control comparison; p=
e × drug treatment). (G) 106 purified neutrophils (purity 98 ± 1%) from 4 healthy volun-
s fluorescens (106 cfu·ml−1). Asterisk denotes increasing doses of Co 101244 reduce ROS
g co-culture with 106 Pseudomonas fluorescens (mean ± sem, p = 0.011; ANOVA, F (3,
ce ROS fluorescence in primary human neutrophils following co-culture with 106 Pseudo-
t al., NMDA receptor modulation of glutamate release in activated
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GluN2B subunit blockade. Co 101244 dose-dependently reduced ROS
production in primary human neutrophils obtained from 4 healthy vol-
unteers (Fig. 7G) following 18 h incubation with Pseudomonas
fluorescens (Fig. 7H).
4. Discussion
Glutamate has been implicated in generating tissue inflammation in
several pathological models [47]. Glutamate is the metabolic precursor
of the chief inhibitory neurotransmitter GABA that, via the GABA-A re-
ceptor, plays a well-established role in modulating macrophage func-
tion [48,49]. The principal finding of our studies is that glutamate may
also contribute to several aspects of neutrophil function via activation
of complexes formed by the NMDAR and associated scaffolding pro-
teins. Neutrophil NMDAR-mediated signalling recapitulates many as-
pects of neuronal NMDAR biology (summarised in Fig. 8). Our
translational clinical data using in vivo murine and ex-vivo human
models suggest a role for NMDAR gating in modulating the neutrophil
inflammatory response to infections relevant to the CNS.
A role for glutamate and (indirectly) NMDAR-mediated signalling
has been implicated in a broad range of immunology-related areas, in-
cluding macrophage biology [11,50,51], lymphocyte function [52], and
neutrophil-mediated lung injury [53]. However, a functional role for
NMDAR in neutrophils has chiefly been inferred through pharmacologic
antagonist studies [54]. Off-target effects of various antagonists includ-
ing K+ channel inhibition [55] and non-specific (anaesthesia-like) ef-
fects on other membrane targets [56] may account for many findings
attributed to (potential) NMDAR involvement [51,54,57–59]. However,
the general anesthetic isoflurane, which suppresses neuronal NMDAR
activity [60], attenuates zymosan-induced lung injury by reducing neu-
trophil NMDAR/TLR2 mediated NADPH oxidase generation of superox-
ide [10]. A further precedent for the involvement of glutamate in innate
immune regulation has been proposed through the observation that
glutamate released by activated human polymorphonuclear cellsFig. 8. Summary of potential role for NMDAR/GluN2B signalling in modifying degree of ROS
activation by DAMPs/PAMPs promotes calcium influx to augment neutrophil ROS generat
antagonism promotes apoptosis in non-activated cells.
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dothelial mGluRs [12]. Akin to previous observations on the location of
glutaminase, [61]. we found that serine racemase is present on the neu-
trophil cell surface and release of D-serine increases in response to PMA
challenge. These data suggest that D-serine acts as a co-agonist recruited
to maintain NMDAR activity in neutrophils, rather than glycine which
inhibits the neutrophil respiratory burst [62]. Thus, the necessary ma-
chinery is in place in human neutrophils for glutamate generated via
glutaminase to activate NMDAR in an auto- and paracrine manner.
As first demonstrated in immune cells [9], the NADPH oxidase-2
(NOX2) isoform is the major source of neuronal ROS produced follow-
ing NMDAR activation by glutamate. In neurons, calcium influx triggers
release of superoxide by activating neuronal NADPH oxidase [7]. Dis-
ruption of the GluN2B NMDAR subunit binding to the scaffolding pro-
tein postsynaptic density protein 95 (PSD-95) blocks phosphorylation
of the critical p47phox subunit of NADPH oxidase [29]. Depending on
the source, and concentration of extracellular glutamate, GluN2B
subunit-containing NMDA receptors contributes to neuronal survival
[45]. Therefore, to further dissect the role of NMDAR-mediated signal-
ling in neutrophil biology, we used GluN2B NMDAR subunit specific
small molecule inhibitors, as well as genetic models of NMDAR subunit
and scaffolding protein deficiency that were originally developed to un-
derstand the role of NMDARs in the brain. The results obtained in this
study support the hypothesis that the neural and immune systems
share key signalling mechanisms of functional relevance [63].
Further insights were afforded from the maturation of HL60 cells
into a neutrophil-like phenotype, whichwas characterized by increased
ROS generation (in response to PMA challenge) and a parallel increase
in GluN2B expression. The role of the GluN2B subunit in generation of
superoxide by the neuronal NADPH oxidase is well established [7].
The NOX2 isoform of NADPH oxidase is the predominate isoform
expressed by both neurons and neutrophils [9]. Since GluN2B-specific
antagonists similarly reduced ROS production in response to PMA and
bacterial challenge in primary neutrophils, this appears to be a con-
served feature of both neural and immune systems. Furthermore, wegeneration in activated neutrophils. Release of glutamate and co-agonist D-serine after
ion. Tonic levels of extracellular glutamate may play a protective role, since GluN2B
t al., NMDA receptor modulation of glutamate release in activated
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ROS generation was reduced in highly purified neutrophils co-
incubatedwith a GluN2B antagonist and Pseudomonas fluorescens, a glu-
tamate producing bacteria. Extracellular calcium augments neutrophil
ROS generation following priming with pro-inflammatory cytokines
[64]. Augmentation of the neutrophil respiratory burst by the presence
of extracellular calcium recapitulates the calcium-dependent role de-
scribed for NMDA-induced NOX2 activation in neurons with NMDA re-
ceptors [7,65]. In further support of this hypothesis, genetic ablation or
small molecule inhibition of PSD-95 attenuated ROS production,
paralleling the role of these pivotal scaffolding proteins in neurons.
The combination of ubiquitous PKC activation through inflammatory li-
gands ungating theNMDAR, and excess release of glutamate, appears to
facilitate this regulatory role for extracellular calcium.
The finding that systemic inflammation (after surgery) is associated
with increased expression of NMDAR in neutrophils obtained from pa-
tients postoperatively is consistent with the upregulation of NMDAR
subunit expression reported in microarray analyses of neutrophils in
patients within 96 h of sustaining major trauma [18]. Specifically, mi-
croarray analysis showed that GluN1 expression was increased ~5-
fold, which was accompanied by ~22-fold upregulation of NMDA
receptor-regulated gene 1 (NARG1).This expression pattern is in con-
trast to the reduced expression of NMDA receptor-regulated genes dur-
ing early postnatal development, when GluN1 receptor expression is
up-regulated [66]. As reported in trauma patients, the GluN2B upregu-
lation was associated with neutrophil dysfunction [67]. The preopera-
tive versus postoperative comparison within the same patient adds
further strength to these findings, and is consistent with previous re-
ports that inhalational anaesthesia interactswith theNMDAR in neutro-
phils [10]. The upregulation of the GluN2B receptor observed in
neutrophils obtained from the systemic inflammatory milieu of the
postoperative environment mirror similar findings in neurons, where
tumour necrosis factor (TNF)-alpha-induces a rapid increase in the sur-
face density of GluN1B subunit in hippocampal neurons [68].
In summary, our results indicate that the auto/paracrine release of
glutamate and D-serine acting on NMDARs contributes to several regu-
latory mechanisms involved in neutrophil biology in a manner analo-
gous to that described in neurons. These data provide further potential
insights into why recruitment of neutrophils may further exacerbate
brain injury through the release of glutamate triggering pathophysio-
logic NMDAR signalling. Shared mechanisms exhibited by circulating
cells that are readily available frompatients with, or at risk from, neuro-
logical disease suggest a potential role for this paradigm to further un-
derstanding of neuropathology.
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